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Edited by Francesc PosasAbstract Outgrowing endothelial progenitor-derived cells
(EPDCs) originate from a novel hierarchy of endothelial progen-
itor cells. In this study, EPDCs isolated from human cord blood
were examined for phenotype and functional features upon
aging. Young or aged EPDCs were similar to human umbilical
vein endothelial cells (HUVECs), in exhibiting typical endothe-
lial phenotypes. However, EPDCs were more sensitive to angio-
genesis inducers or inhibitors in proliferation and migration. In
addition, EPDCs underwent senescence markedly slowly with
sustained endothelial NO synthase expression and activation,
and their ability to undergo capillary morphogenesis was
retained throughout longterm culture. Thus, these results suggest
that a homogenous population of EPDCs derived from clono-
genic expansion may provide an eﬀective vasculogenesis tool.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Endothelial progenitor cells (EPCs) can contribute to post-
natal vasculogenesis in tissue ischemia, wound healing, and tu-
mor growth [1–3]. Early EPCs with the limited proliferating
potential (for less than 3 weeks) were initially characterized
as a cell type with postnatal vasculogenic capacity by Asahara
et al. [1,2]. These observation led to clinical trials of therapeu-
tic application of EPCs in cardiovascular disease [4,5]. Later,
several groups reported a diﬀerent cell type with high expan-
sion capacity that appears at a late stage [6–9]. The cells were
named endothelial progenitor-derived cells (EPDCs) or late
EPCs. In in vitro culture, early EPCs form adherent spindle-
shaped cells at day 7–14, and die after 3 weeks. In the case
of EPDCs, they have been reported to diﬀerentiate from a
subset of EPCs after 2 weeks, show exponential growth at
4–8 weeks and live up to 12 weeks. In particular, cord*Corresponding author. Fax: +82 2 532 0575.
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doi:10.1016/j.febslet.2007.05.010blood-derived EPDCs have been shown to have a greater pro-
liferative rate and expandability than those of adult peripheral
blood-derived EPDCs [6].
For in vitro angiogenesis assays, human umbilical vein endo-
thelial cells (HUVECs) have been used frequently and com-
monly. However, HUVECs, mature endothelial cells, that
are primarily cultured from human cord vein vessel, are chan-
ged in phenotypes and signal pathways during long term cul-
ture [10,11]. The growth of HUVECs slows down after
about 19–22 population doublings and the cells are used
between passages 2 and 8 (about 4 weeks). In addition, the cul-
ture of these cells is sometimes complicated by contamination
with ﬁbroblasts. In the case of EPDCs, they constitute a
homogenous population by clonogenic expansion. Moreover,
EPDCs have been shown to have tissue repair capability
through neovasculogenesis in a limb ischemia model of mouse,
suggesting a potential for cell therapy of vascular grafts [8].
However, the shape of cultured EPDCs is very similar to HU-
VECs and the isolation of EPDCs is not always successful,
resulting in a frequency of about 30% of total blood samples
under our experimental conditions. So, considering that HU-
VECs and EPDCs are derived from cord vessel wall and cord
blood, respectively, the possibility cannot be excluded that
EPDCs might appear from an in vitro artifact, like immortal-
ization or in vitro transformation of endothelial cells that
emerged from vessel walls. Therefore, we addressed the ques-
tion of how EPDCs are diﬀerent from HUVECs in phenotypes
and functional features during long-term culture. In these
experiments, we show that EPDCs, in contrast to HUVECs,
retain endothelial characteristics in phenotype and function
during a long-term culture period, and only slowly undergo
senescence, not being immortalized, thereby suggesting that
EPDCs may be an eﬀective vasculogenesis tool for in vitro as-
says and cell therapy.2. Materials and methods
2.1. Cell culture
The Institutional Review Board at the Catholic University of Korea
College of Medicine approved all protocols. Cord blood and cords
were obtained from donors with informed consent. Mononuclear cells
(MNCs) were isolated from human cord blood using Ficoll-Hypaqueblished by Elsevier B.V. All rights reserved.
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MNCs were plated into a dish coated with 10 lg/ml human ﬁbronectin
(Sigma, St. Louis, MO) and incubated in Medium 199 (M199, JBI,
Daegu, Korea) supplemented with 20% fetal bovine serum (FBS,
Gibco BRL, Grand Island, NY), 30 lg/ml endothelial cell growth sup-
plement (ECGS, Sigma), 90 lg/ml heparin (Sigma) and 1% penicillin–
streptomycin (Gibco BRL). After changing to fresh media every 3–4
days for 15–21 days, an emerging EPDC clone was trypsinized, and
transferred to 1% gelatin-coated dishes for subculture. Human umbil-
ical vein endothelial cells (HUVECs) were cultured as described
previously [12].
2.2. Cell proliferation potential
At subconﬂuence, cells were detached and counted. The number of
divisions was estimated using the following equation: (Ln(number of
cells counted/number of cells at the beginning of the assay)/Ln2) [7].
2.3. Reverse transcriptase polymerase chain reaction (RT-PCR)
RNA of EPDCs or HUVECs was extracted by use of the Trizol
reagent (Life Technologies, San Diego, CA). First-strand cDNA was
synthesized using the reverse transcription system (Promega, Madison,
WI), and was used for the ampliﬁcation of each cDNA by Super Taq
PLUS version (Super Bio Co. LTD, Seoul, Korea). The PCR primer
sequences used for RT-PCR are listed in Table 1. PCR conditions were
95 C for 5 min, followed by 30 cycles (25 cycles for GAPDH) of 95 C
for 1 min, 55–63 C for 1 min, and 72 C for 1 min, and ending with
72 C for 10 min.
2.4. FACS analysis
FACS analysis was performed on EPDCs and HUVECs collected
after trypsinization as described previously, except vWF and VE-cad-
herin [12]. For detection of VE-cadherin, cells were detached by treat-
ment of 4 mM EDTA for less than 5 min, washed twice, and blocked
with 0.5% BSA and 1 lg human immunoglobulin (IgG) in PBS. vWF
was detected as reported by Lin et al. [13]. Binding of anti-vWF
(mouse monoclonal, Dako, Glostrup, Denmark) antibody was visual-
ized with Cy3-conjugated goat anti-mouse IgG (Chemicon, Temecula,
CA). Anti-CD31, anti-CD34 (mouse monoclonal, Becton Dickinson,
San Jose, CA), anti-CD105 (mouse monoclonal, Serotec, UK), and
anti-VE-cadherin (mouse monoclonal, R&D, Minneapolis, MN) anti-
bodies were used directly as the PE- or FITC-conjugated form.Table 1
List of primer sequence
Gene Nucleotide sequence
PK5 5 0-CAGTATCGATCACTCCTTCCGAAGAAGAC
3 0-CTGATCTAGATCAAAATGAAGGGGCCGC
Endostatin 5 0-CAGTATCGATACATACTCATCAGGACTTTC
3 0-CTGATCTAGACTATTTGGAGAAAGAGGTC
KDR F-GTGATTGCCATGTTCTTCTG
R-GAGGATCTTGAGTTCAGACA
Flt-1 F-GGTCTTTGCCTGAAATGGTGAG
R-GACTGTTGCTTCACAGGTCAGA
Tie-2 F-ATGCGTCAACAAGCTTCCTTCC
R-CACCTAAGCTTACAATCTGGCC
vWF F-ACGCTCCTTCTCGATTATTGGG
R-CAGAGGAGATGTTGCATGAGC
VE-cadherin F-CTCAGTCATCTCTGAGAC
R-AATCCAGAGGCTTCATGG
Integrin av F-CGTCTTCCCGGATGTTTCTTCT
R-CTGCTCTTGGAACTCCTGAAAC
Integrin a5 F-TACCAGTCCTTGCAGTGGTTCG
R-CCACTGAATTCACCAACAGCCA
Integrin b1 F-CAGGAAGGAATGCCTACTTCTG
R-CCCATCTCCAGCAAAGTGAAAC
Integrin b3 F-CCTGAAGGAGAATCTGCTGAAG
R-GATGCATCATTCCTCACGCCAA
Integrin b5 F-AAAGTGGAGTTGTCAGTCTGGG
R-ACAGGAGAAGTTGTCGCACTCA
GAPDH F-ATGTTCGTCATGGGTGTGAACC
R-GGCAGGTTTTTCTAGACGGCAG2.5. Expression and puriﬁcation of angiogenesis inhibitors
The recombinant proteins of PK5 and endostatin were expressed in
Pichia using EasySelectPichia Expression Kit (Invitrogen, Carlsbad,
CA) as follows. cDNA fragments were obtained from Dr. Yeup Yoon
(PK5, Mogam Biotechnology Research Institute, Korea) and Dr. Soo-
Ik Chang (mouse endostatin, Chungbuk National University, Korea).
DNA fragments encoding the amino acids of human plasminogen
kringle 5 (PK5, Thr456–Phe546 of plasminogen) and endostatin
(His132–Lys315 of mouse a1 (XVIII)) were ampliﬁed by PCR with
Pfu polymerase (Stratagene, La Jolla, CA) and PK5 primers or endo-
statin primers (Table 1), and subcloned into the Cla I–Xba I site of
pPICZa-C. The insert DNA was cut with SacI and introduced into
Pichia pastoris GS115 (pPICZa-C/PK5) or X-33 (pPICZa-C/endo-
statin) by electroporation. After the selection of PK5 or endostatin-
expressing clones, expression in a large-scale culture and puriﬁcation
were performed by a similar method to that reported previously for
the recombinant kringles 1–2 of tissue-type plasminogen activator
(TK1–2) protein [14].2.6. Cell proliferation assay
Cell proliferation assays were performed using a thymidine incorpo-
ration assay as described previously [15].2.7. Cell migration assay
The migration of EPDCs and HUVECs was evaluated in a modiﬁed
Boyden chamber assay as described previously [14].
2.8. In vitro tube formation on Matri-gel
Twohundred andﬁftymicroliters of chilledMatri-gel (BD)was added
in eachwell of a chilled 24well plate.After 30 min of incubation at 37 C,
250 ll M199 medium containing 4 · 104 cells/well was added onto the
solidiﬁedMatri-gel. After 18 h of incubation, the cells were stained with
hematoxylin and ﬁve representative ﬁelds were photographed. Images
were analyzed in Image J v.1.34s (http://rsb.info.nih.gov/ij/) for deter-
mining tube density.
2.9. Senescence associated (SA)-b-galactosidase assay
The cells were washed, ﬁxed, and incubated overnight at 37 C with
X-gal chromogenic substrate at pH 6.0 following the conventional pro-
tocol for SA-b-gal staining [16]. After taking pictures of ﬁve randomly
selected ﬁelds, the cells were washed with PBS and 500 ll DMSO was
added to each well for dissolving the stain, and incubated at 37 C for
30 min, followed by measurement of absorbance at 595 nm.
2.10. Telomerase assay
Telomerase activity was measured with 5 lg protein by the Tel-
oTAGGG Telomerase PCR ELISAPLUSKit according to the manufac-
turer’s instructions (Roche Applied Science, Germany).
2.11. Western blot
Cell lysate (50 lg protein) was resolved on SDS–PAGE gel and
transferred to a nitrocellulose membrane. The membrane was incu-
bated with an antibody against phospho-eNOS, eNOS, ERK 1/2 (Cell
Signaling, Danvers, MA), b-actin, b-tubulin (Sigma) or GAPDH
(R&D, Minneapolis, MN), followed by binding with the correspond-
ing secondary antibody conjugated to horseradish peroxidase. The
binding was detected by enhanced chemiluminescence (ECL plus,
Amersham, Germany).3. Results and discussion
3.1. Comparison of growth kinetics and phenotypes
Under our experimental conditions, we were able to isolate
EPDCs at a frequency of 3 donors out of a total of 9 donors
from the culture of mononuclear cells (MNCs) isolated from
the cord blood of several infants. EPDCs started to appear
in culture dishes 17 days after seeding of MNCs and about
ten individual colonies were obtained at once. As shown in
Fig. 1A, the clone became larger over time and grew exponen-
Fig. 1. The comparison of growth kinetics and phenotypes. (A) Population doubling of EPDCs isolated from diﬀerent individual cord blood samples
was compared with that of HUVECs (left). Ex vivo cultivation day 0 (D0) indicates the day when MNCs or HUVECs were isolated for initiating
in vitro culture. Representative photomicrographs of an EPDC colony were captured (right, 100·). (B) The representative pictures of each cell type
were captured upon aging (200·). RT-PCR (C) and FACS analyses (D) were performed on various endothelial cell markers and vascular integrins.
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compared, the population doubling curves demonstrate that
both EPDCs, derived from two donor bloods, have a higher
proliferation potential than HUVECs (Fig. 1A). EPDCs
reached growth arrest after about 40 population doublings,
whereas HUVECs reached growth arrest faster, after 27 popu-
lation doublings, in about 50 days. Subculture of EPDCs was
maintained for more than 3 months without any apparent
signs of replicative senescence. However, the growth rate of
EPDCs decreased after 110 days, thereby indicating that
EPDCs eventually stop growing, not being immortalized. Both
young HUVECs (D10, 10 days after initiating ex vivo culture)
and young EPDCs (D50) appeared as similar cobblestone-
shapes. In accordance with several established studies showing
that cells entering senescence become enlarged and ﬂattened,
aged HUVECs (D50) became larger and ﬂatter than aged
EPDCs (D100) (Fig. 1B).When we examined the expression of typical endothelial cell
markers, including KDR, Flt-1, Tie-2, vWF, VE-cadherin,
CD34, CD31, and CD105, by RT-PCR and FACS analyses,
we could not detect any marked diﬀerence between EPDCs
and HUVECs (Fig. 1C and D). Thus, at present, the diﬀerence
in phenotype between EPDCs and HUVECs is not clear. More
precise analysis methods including microarray analysis, which
allows analysis of many genes at once, will be desirable to dif-
ferentiate between HUVEC and EPDC phenotypes.
3.2. EPDCs are sensitive to various angiogenesis modulators
When we tested the functional properties of EPDCs, we
found that basal levels of endothelial proliferation and migra-
tion were higher in young cells than in aged cells in both
EPDCs and HUVECs (Fig. 2A and C). In particular, EPDCs,
young or aged, showed high sensitivity to growth and move-
ment stimuli, whereas aged HUVECs of the same ex vivo
Fig. 2. Comparison of sensitivities to angiogenesis inducers or inhibitors in cell proliferation and migration. The [3H] thymidine-incorporation assay
was performed on young or aged EPDCs and HUVECs, for evaluating cell growth stimulated by bFGF (A) and the anti-proliferative eﬀect of PK5
(B). VEGF-stimulated cell migration (C), and anti-migrative eﬀect of PK5, TK1–2 and endostatin (D) were assessed. The inhibitory eﬀects were
shown as a percentage of stimulated growth (cpm) (B) or migration (cell number) (D) in the absence of inhibitor. Values represent the mean of three
independent experiments (means ± S.E.). *P < 0.05, **P < 0.01, compared with non-treated cells.
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tion of proliferation and marked induction of migration by
bFGF or VEGF. In both cell types, young cells displayed more
sensitivity in cell proliferation to the bFGF stimulus than did
aged cells.
Next, we tested if EPDCs are sensitive to endothelial-selec-
tive angiogenesis inhibitors including plasminogen kringle 5
(PK5), tissue-type plasminogen activator kringles 1–2 (TK1–
2), and endostatin. Interestingly, PK5 dose-dependently inhib-
ited cell proliferation signiﬁcantly only for young EPDCs
(IC50 = 60 nM) and HUVECs (D10, IC50 = 250 nM)
(Fig. 2B). Aged HUVECs (D50) did not show any signiﬁcant
inhibition of proliferation by PK5. In the migration assay,
all the inhibitors tested showed inhibition in young EPDCs
(PK5, IC50 = 100 nM; TK1–2 IC50 = 80 nM; endostatin,
IC50 = 80 nM) (Fig. 2D). Aged HUVECs showed a little high-
er IC50’s than young EPDCs at the same age (D50) (PK5,
IC50 > 500 nM; TK1–2 IC50 = 100 nM; endostatin,
IC50 = 100 nM). Upon aging, the sensitivity of EPDCs to the
inhibitors in cell migration decreased. Interestingly, inhibitors
showed inhibitory activity in migration of aged cells of both
cell types, unlike the diﬀerence in eﬀects on proliferation.
Overall, EPDCs at day 50, the same age as aged HUVECs,
showed high sensitivity to angiogenesis inducers and inhibitors
in both proliferation and migration, suggesting that EPDCs
have more potentiality for vasculogenesis, and that they can
be used more eﬀectively in migration and proliferation assays.3.3. Diﬀerent capacity for capillary tube formation between aged
EPDCs and HUVECs
In the in vitro tube formation assay, young EPDCs formed
capillary-like structures on Matri-gel (Fig. 3). When we com-
pared the capacity for capillary tube formation between young
and aged cells, aged HUVECs showed a low capacity for cap-
illary tube formation, although they showed a high motility
upon VEGF induction. On the other hand, aged EPDCs were
able to form capillary tubes fully, suggesting that EPDCs
retain the capability of capillary morphogenesis through
long-term culture. In previous reports, senescence has been
reported to progress more increased adhesion to the extracell-
uar matrix while losing cell–cell contacts [17,18]. Therefore, the
progression of senescence in HUVECs seems to result in a
decrease in their capacity to form tubes.3.4. Markedly delayed senescence in EPDCs
We investigated the senescence levels of EPDCs and HU-
VECs through SA-b-galactosidase staining, which is widely
used as a biomarker of senescence. Aged EPDCs showed much
fewer SA-b-gal positive cells than aged HUVECs, while their
young cells showed few stained cells (Fig. 4A). When EPDCs
were stained at the growth-arrest point (at day 130), EPDCs
were also strongly stained (data not shown), suggesting that
EPDCs also undergo senescence eventually, but do so much
more slowly than HUVECs. Next, telomerase activity was
Fig. 4. Cellular senescence of EPDCs and HUVECs. (A) Young or
aged cells were stained by the SA-b-galactosidase reaction. (B) The
cells were assessed for relative telomerase activity (RTA).
Fig. 3. Formation of tube-like structure on Matri-gel. After young or
aged EPDCs (D50,D100) and HUVECs (D10,D50) were incubated
for 18 h on Matri-gel, the representative pictures were captured (100·),
and tube density was analyzed.
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telomerase. As shown in Fig. 4B, telomerase activity was
reduced drastically in HUVECs upon aging, whereas aged
EPDCs showed telomerase activity at a certain level, albeit
at a reduced one, thereby corresponding well with the data
obtained from SA-b-galactosidase staining. Thus, these results
indicate that EPDCs are not derived from artifacts of in vitro
cell culture, such as immortalization or transformation of ves-
sel cells, and that they undergo senescence slowly.
Next, we investigated the expression of eNOS and Akt and
its phosphorylation status since aging of endothelial cells has
been reported to be associated with reduced eNOS expression
and decreased NO synthesis [19]. Indeed, eNOS protein
expression and phosphorylation levels were drastically reduced
in aged HUVECs (Fig. 5A and B). However, aged EPDCs, as
well as young EPDCs, showed certain levels of expression and
phosphorylation of eNOS, indicating no signs of senescence.
Interestingly, the expression level of Akt and ERK 1/2 did
not change upon aging, but the mean expression level of
b-tubulin and b-actin decreased in HUVECs only, although
there was some variation in the expression level of b-tubulin
and b-actin among the donor types of HUVECs. This result
corresponds well with a previous report that b-actin expression
was down-regulated in rat gastric mucosa upon senescence
[20]. At present, albeit with some questionable points, the
results could suggest that the decreased expression of cytoskel-
eton proteins b-actin and b-tubulin, which are involved in cell
movement and shape, might be related to the loss of tube for-mation ability and can be a characteristic of endothelial cells
during senescence.
Very recently, the inhibition of cellular senescence in HU-
VECs by nitric oxide has been reported [21]. Therefore, we
tested whether inhibition of eNOS causes progression of senes-
cence in EPDCs, as it does in HUVECs. Indeed, treatment
with L-NAME (a NOS inhibitor) decreased the proliferation
of EPDCs as they got older and showed more SA-b-gal stained
cells, when compared with treatment with D-NAME (negative
control) (Fig. 5C). Such an eﬀect was also detected in two
other EPDC clones, clones 2 and 3. Telomerase activity was
also reduced upon L-NAME treatment compared to D-NAME
treatment (Fig. 5D). Thus, all the results suggest that the delay
of senescence in EPDCs may be due to a steady eNOS expres-
sion and activation (and possibly NO production).
In summary, we found that EPDCs show high sensitivity to
angiogenesis inducers and inhibitors and also undergo delayed
senescence, even though both EPDCs andHUVECs are derived
from infant cord blood and tissue. In particular, a large diﬀer-
ence in senescence levels between EPDCs and HUVECs is man-
ifested in in vitro tube formation capability, expression of eNOS
and b-tubulin, and phosphorylation of eNOS. Moreover,
Fig. 5. Diﬀerential expression of eNOS, b-tubulin and b-actin in aged EPDCs and HUVECs and eﬀect of NO on EPDC senescence. (A)
Phosphoryation of eNOS Ser1177 and expression of eNOS, Akt, ERK1/2, b-tubulin, b-actin and GAPDH were determined by Western blot analysis.
GAPDH was used as a loading control. (B) The densitometric quantiﬁcation of the Western blots was performed. The density of each protein band
was normalized with that of GAPDH. Values represent the mean of three independent Western blot experiments (means ± S.E.). (*P < 0.01
compared with young cells). (C and D) EPDCs were cultivated in the presence of L-NAME or D-NAME (Sigma) at 100 lM from ex vivo cultivation
day 50 to day 82, with replacement of new medium every 48 h. SA-b-galactosidase staining (C) and assessment of relative telomerase activity (D) were
performed at day 82 after cultivation in the presence of L-NAME or D-NAME. Each point represents the mean ± S.E. of results from three
experiments.
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clonogenic expansion of EPCs, not from transformed endothe-
lial cells. In addition, cultured EPDCs can be stored more safely
in a liquid nitrogen tank than can HUVECs, because thawing
and freezing procedures do not inﬂuence their growth kinetics
or cell adhesion signiﬁcantly, in contrast to HUVECs (data
not shown). Therefore, all the present ﬁndings suggest that cord
blood-derived EPDCsmay be used eﬃciently in studies of endo-
thelial cell function and possibly in cell therapy.
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